2015 started off with a bang, with a focus on brain cancer patients and new treatment options for recurrent glioblastoma (rGBM).
By Dellann Elliott Mydland, founder and president of the Chris Elliott Fund
2015 started off with a bang, with a focus on brain cancer patients and new treatment options for recurrent glioblastoma (rGBM). I am delighted to finally be able to blog about a new clinical trial that is recruiting at the Seton Brain & Spine Institute in Austin, Texas. To learn more about the Seton Brain & Spine Institute, click here
The principal investigator at Seton is Brian D. Vaillant, MD. The contact for this trial if you are interested in getting information and possibly participating is Heidi Herdon, RN, 513-324-7000, ext. 77713 (email@example.com
). I am proud to say that Santosh Kesari, MD, director of neuro-oncology at Moores UCSD Cancer Center and one of CEF’s medical advisory board members, is the study director. To learn more about NCT02296580, click here
Watch this video
to learn about how the Nativis Voyager System works on solid tumors in canines. Findings from this study were so positive, the data were used to get human trials started for rGBM. I have eagerly been sitting on the sidelines watching this technology, the canine clinical trial results, and potential treatment for rGBM for the last three years. I am now delighted to see this potential new treatment for rGBM become available for brain cancer patients.
If you are in the central Texas area and interested in enrolling in this trial, please contact Heidi Herdon, and if you are in the Pacific Northwest and interested in learning more about this trial, including enrollment, please feel free to contact me directly at Dellann@ChrisElliottFund, at 425-785-8489, or at www.ChrisElliottFund.org
Let’s keep the momentum going!